Q-omics provides the consensus-scored TRBV16 profile across patient tissues and cancer cell-line models. TRBV16 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TRBV16 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRBV16 RNA expression shows 11,501 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight STAD, KIRC, and PDAC as cancer lineages where TRBV16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV16 survival associations across molecular data types. TRBV16 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV16 RNA expression–survival associations across cancer types. High TRBV16 expression shows unfavorable associations in KICH, KIRC, ACC, LUSC and MESO, but favorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for TRBV16 RNA expression.
This table summarizes TRBV16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV16 shows lower tumor expression in PAAD, COAD and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher TRBV16 RNA expression in tumor versus normal tissue (log2 FC = +0.144, t-test p = .035).
This table shows molecular features associated with TRBV16 in patient tissues and cancer cell lines. In patient samples, TRBV16 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
